AXQ Capital LP Buys New Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

AXQ Capital LP purchased a new stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 23,578 shares of the company’s stock, valued at approximately $91,000.

Other hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Larimar Therapeutics during the fourth quarter valued at about $52,000. Quest Partners LLC grew its holdings in Larimar Therapeutics by 171.1% during the 3rd quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock valued at $60,000 after buying an additional 5,796 shares in the last quarter. Virtu Financial LLC bought a new stake in Larimar Therapeutics in the 3rd quarter worth approximately $71,000. SG Americas Securities LLC raised its holdings in shares of Larimar Therapeutics by 35.1% during the 4th quarter. SG Americas Securities LLC now owns 19,391 shares of the company’s stock worth $75,000 after acquiring an additional 5,042 shares in the last quarter. Finally, Quarry LP grew its holdings in shares of Larimar Therapeutics by 50.0% in the third quarter. Quarry LP now owns 12,000 shares of the company’s stock valued at $79,000 after purchasing an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Trading Down 10.2 %

Shares of NASDAQ:LRMR opened at $2.28 on Tuesday. Larimar Therapeutics, Inc. has a 12 month low of $2.25 and a 12 month high of $11.20. The company has a market capitalization of $145.48 million, a price-to-earnings ratio of -1.98 and a beta of 0.99. The firm’s 50-day moving average is $3.16 and its 200 day moving average is $5.24.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LRMR shares. Truist Financial started coverage on shares of Larimar Therapeutics in a research note on Wednesday, January 29th. They set a “buy” rating and a $18.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Larimar Therapeutics in a report on Friday, January 24th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $20.13.

Larimar Therapeutics Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.